XRTX
XORTX Therapeutics·NASDAQ
--
--(--)
--
--(--)
7.21 / 10
Outperform
Analyst coverage is absent, but fund‑flow sentiment is strong (7.21/10) with positive inflows across all size categories. Capital is flowing in, supporting the stock despite the lack of analyst guidance.
Fund Flow Rating
What is the analyst consensus for XRTX?
- XRTX holds a Neutral analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 7.21/10 (Outperform).
